Anti-obesity drugs and neural circuits of feeding

被引:80
作者
Adan, Roger A. H. [1 ]
Vanderschuren, Louk J. M. J. [1 ]
la Fleur, Susanne E. [1 ]
机构
[1] UMC Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurosci & Pharmacol, NL-3584 CG Utrecht, Netherlands
关键词
D O I
10.1016/j.tips.2008.01.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most of the drugs that have entered the market for treating obesity were originally developed to treat psychiatric diseases. During the past decade, understanding of the neural circuits that underlie food intake has increased considerably. Different aspects of ingestive behavior such as meal termination, meal initiation and overconsumption of highly rewarding and palatable foods are modulated by different neuroanatomical structures. Integration of the action of many signaling molecules (e.g. hormones, neurotransmitters and neuropeptides) in these structures results in a response that, ultimately, modulates food intake. Thus, the type of drug required by an obese patient might depend on the individual cause of obesity. In this article, we summarize the neural circuits that regulate food intake and we provide a framework for understanding how obesity drugs function. Several potential drug targets are expressed in different neural circuits, implying that current and future obesity drugs act on partially overlapping systems that control food intake.
引用
收藏
页码:208 / 217
页数:10
相关论文
共 123 条
  • [21] Plasma membrane and vesicular glutamate transporter mRNAs/proteins in hypothalamic neurons that regulate body weight
    Collin, M
    Bäckberg, M
    Ovesjö, ML
    Fisone, G
    Edwards, RH
    Fujiyama, F
    Meister, B
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2003, 18 (05) : 1265 - 1278
  • [22] Studies on the physiological functions of the melanocortin system
    Cone, Roger D.
    [J]. ENDOCRINE REVIEWS, 2006, 27 (07) : 736 - 749
  • [23] Valvular heart disease associated with fenfluramine-phentermine
    Connolly, HM
    Crary, JL
    McGoon, MD
    Hensrud, DD
    Edwards, BS
    Edwards, WD
    Schaff, HV
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) : 581 - 588
  • [24] The obesity pipeline: current strategies in the development of anti-obesity drugs
    Cooke, Dunstan
    Bloom, Steve
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (11) : 919 - 931
  • [25] Gastrointestinal regulation of food intake
    Cummings, David E.
    Overduin, Joost
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (01) : 13 - 23
  • [26] Ghrelin and the short- and long-term regulation of appetite and body weight
    Cummings, David E.
    [J]. PHYSIOLOGY & BEHAVIOR, 2006, 89 (01) : 71 - 84
  • [27] Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial
    Davidson, MH
    Hauptman, J
    DiGirolamo, M
    Foreyt, JP
    Halsted, CH
    Heber, D
    Heimburger, DC
    Lucas, CP
    Robbins, DC
    Chung, J
    Heymsfield, SB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03): : 235 - 242
  • [28] Common genetic variations in CCK, leptin, and leptin receptor genes are associated with specific human eating patterns
    de Krom, Mariken
    van der Schouw, Yvonne T.
    Hendriks, Judith
    Ophoff, Roel A.
    van Gils, Carla H.
    Stolk, Ronald P.
    Grobbee, Diederick E.
    Adan, Roger
    [J]. DIABETES, 2007, 56 (01) : 276 - 280
  • [29] Gastrointestinal hormones and regulation of food intake
    Dhillo, WS
    Bloom, SR
    [J]. HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 846 - 851
  • [30] Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function:: A combined in vivo electrophysiological and microdialysis study
    Di Giovanni, G
    De Deurwaerdére, P
    Di Mascio, M
    Di Matteo, V
    Esposito, E
    Spampinato, U
    [J]. NEUROSCIENCE, 1999, 91 (02) : 587 - 597